Contraceptive Usage in Female Survivors of Young Adult Cancers [17F]

    loading  Checking for direct PDF access through Ovid



Cancer survivors may be less likely than the general population to use effective methods of contraception, but prior studies were small.


In a population-based study, we recruited reproductive-aged (22-45 years) women, diagnosed with cancer between the ages of 20-35 years and at least 2 years post-diagnosis. Women with no cancer history were recruited for comparison. Exclusion criteria included having a hysterectomy or bilateral oophorectomy. Women reported on contraceptive use (pills, patch, ring, mini-pills, Depo Provera, implant, hormonal and non-hormonal intrauterine device, and tubal ligation) in the past year.


Among survivors (n=960), 38.4% reported using a WHO Tier I/II contraceptive method in the past year compared to 47.5% of comparison women (n=992). Long-acting reversible contraceptive (LARC) was more common among contracepting survivors (30.9%) than among contracepting comparison women (23.4%). Among cancer survivors contraceptive use was associated with being younger than 35 years at interview (odds ratio [OR]: 2.04, 95% confidence interval [CI] 1.55, 2.67), being younger than 30 years at diagnosis (OR 1.81, 95% CI 1.38, 2.37), identifying as white (OR 1.54, 95% CI 1.13, 2.10), not having chemotherapy (OR 1.43, 95% CI 1.10, 1.86), and being nulligravid at cancer diagnosis (OR 1.31, 95% CI 1.01, 1.69). Breast cancer survivors were less likely to have used birth control in the past year (OR 0.46, 95% CI 0.34, 0.62) compared with all other cancer types.


While the overall rate of contraceptive use was lower among cancer survivors than among comparison women, survivors using contraception were more likely to use LARC methods.

Related Topics

    loading  Loading Related Articles